FDA Adds Bladder Cancer Warnings to Takeda ' s Actos
The U.S. FDA has concluded that use of Takeda ' s Actos (pioglitazone), a type 2 diabetes medicine, may be linked to an increased risk of bladder cancer and has approved label updates.
Source: PharmaManufacturing.com - Category: Pharmaceuticals Source Type: news
More News: Actos | Bladder Cancer | Cancer | Cancer & Oncology | Diabetes | Diabetes Type 2 | Endocrinology | Pharmaceuticals | Warnings